{"schema_version":"1.0","type":"article","title":"FDA Rejects Akeso's Bispecific: PFS Was Not Enough","url":"https://drugnews.com.tw/articles/2026-11-17-akeso-summit-ivonescimab-fda-crl-overall-survival-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-17-akeso-summit-ivonescimab-fda-crl-overall-survival-en.md","lang":"en","date":"2026-11-17","publish_at":"2026-11-17T08:00:00+08:00","updated_at":"2026-11-17","category":"商業分析系列","topic":"臨床與 CMC","tags":["Akeso","Summit Therapeutics","ivonescimab","FDA","PD-(L)1×VEGF"],"summary":"On November 15, 2026, Summit announced an FDA complete response letter for ivonescimab. The HARMONi primary OS analysis yielded p=0.057, missing the prespecified 0.0448 threshold.","key_points":["On November 15, 2026, Summit announced an FDA complete response letter for ivonescimab. HARMONi primary OS yielded p=0.057, missing the 0.0448 threshold.","The original Akeso license was worth up to $5 billion. Following the 2024 expansion, cumulative upfront payments reached $515 million, with up to $4.555 billion in milestones.","HARMONi-3 squamous-cohort primary PFS and early interim OS analyses are expected in Q4 2026; non-squamous PFS analysis is expected in H1 2027."],"facts":[{"claim":"Summit announcement of an ivonescimab CRL","value":"2026-11-15","unit":"date","as_of":"2026-11-15","source":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx","note":"Summit page displayed a Cloudflare challenge; Business Wire page was unreachable. Checked the same company release reproduced by FT; no claim that the Summit page opened successfully."},{"claim":"HARMONi enrollment and enrollment in China","value":[438,273],"unit":"patients","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"claim":"HARMONi primary PFS reduction in progression or death risk","value":48,"unit":"%","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"claim":"HARMONi primary OS reduction in death risk","value":21,"unit":"%","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"claim":"HARMONi primary OS p-value and significance threshold","value":[0.057,0.0448],"unit":"p","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"claim":"Primary OS p-value minus significance threshold","value":0.0122,"unit":"p","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival","note":"0.057-0.0448; the numerical p-value gap is not an effect-size measure."},{"claim":"HARMONi primary median OS: ivonescimab plus chemotherapy and chemotherapy","value":[16.8,14],"unit":"months","as_of":"2025-09-07","source":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"claim":"HARMONi later post hoc OS HR and corresponding risk reduction","value":[0.76,24],"unit":"HR; %","as_of":"2026-11-04","source":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/default.aspx","note":"Post hoc, nominal analysis; it does not replace the prespecified primary OS analysis."},{"claim":"Original license execution date and territories","value":"2022-12-05; US, Canada, Europe, Japan","unit":"date; territories","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm"},{"claim":"Original license upfront payment and maximum total value","value":[500,5000],"unit":"USD million","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm","note":"Original agreement; do not mix these amounts with the post-2024-expansion totals."},{"claim":"2024 expansion upfront payment and additional commercial milestones","value":[15,55],"unit":"USD million","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm","note":"Expanded to Latin America, the Middle East and Africa."},{"claim":"Cumulative upfront payments, regulatory milestones and sales milestones after expansion","value":[515,1050,3505],"unit":"USD million","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm"},{"claim":"Maximum remaining milestones and lifetime deal value after expansion","value":[4555,5070],"unit":"USD million","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm","note":"1050+3505=4555; 500+15+4555=5070."},{"claim":"Substantial doubt about going concern in financial statements as of 2026-06-30","value":"substantial doubt","unit":"financial statement","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm","note":"Filed 2026-07-23; this historical as-of statement does not assert that the status remained unchanged after the AstraZeneca investment."},{"claim":"AstraZeneca investment, outstanding-share ownership and fully diluted ownership","value":[2000,12,10.6],"unit":"USD million; %; %","as_of":"2026-09-28／2026-10-05","source":"https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment-summit.html","note":"Announced 2026-09-28; closing separately checked against the official AstraZeneca 2026-10-05 release."},{"claim":"Merck-LaNova upfront payment, milestone ceiling and total deal ceiling","value":[588,2700,3288],"unit":"USD million","as_of":"2024-11-14","source":"https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/","note":"588+2700=3288."},{"claim":"Pfizer-3SBio upfront payment, milestone ceiling and total deal ceiling","value":[1250,4800,6050],"unit":"USD million","as_of":"2025-05-19","source":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio","note":"1250+4800=6050; a separate 100 million equity investment is excluded from the licensing total."},{"claim":"BMS-BioNTech upfront payment, committed payments, milestone ceiling and total deal ceiling","value":[1500,2000,7600,11100],"unit":"USD million","as_of":"2025-06-02","source":"https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple-Solid-Tumor-Types/default.aspx","note":"1500+2000+7600=11100; BNT327 targets PD-L1 and VEGF-A."},{"claim":"Combined maximum total value of the four current agreements","value":25508,"unit":"USD million","as_of":"2026-07-23","source":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm","note":"5070+3288+6050+11100=25508; individual payments also added from references 7, 8 and 13."},{"claim":"Sintilimab CRL date and FDA recommendation","value":"2022-03-24; additional multiregional non-inferiority study with OS endpoint","unit":"date; recommendation","as_of":"2022-03-24","source":"https://investor.lilly.com/news-releases/news-release-details/lilly-announces-complete-response-letter-sintilimab-combination"},{"claim":"Keytruda full-year 2025 product sales","value":31641,"unit":"USD million","as_of":"2026-02-03","source":"https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/","note":"Keytruda product line only; Qlex excluded. Unverified indication-level sales rankings removed."},{"claim":"HARMONi-3 squamous and non-squamous analysis schedule","value":"squamous primary PFS + early interim OS Q4 2026; non-squamous PFS H1 2027","unit":"planned analyses","as_of":"2026-11-04","source":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/default.aspx","note":"Company expectations; the PFS schedule is not described as a confirmatory OS result."},{"claim":"Five positive Phase III trials, May 2024 China approval and over 100,000 patients treated commercially in China","value":"5; 2024-05; >100000","unit":"trials; date; patients","as_of":"2026-11-15","source":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx","note":"The company defines positive as significance on at least one prespecified primary endpoint; this does not claim that HARMONi OS succeeded."},{"claim":"AP505 mechanism and license","value":"PD-L1×VEGF; Tasly; Greater China excluding Taiwan","unit":"targets; licensee; territories","as_of":"2019-07-29","source":"https://www.apbioinc.com/news-detail12.htm"},{"claim":"HARMONi-2 head-to-head PFS advantage","value":"HR 0.51; median 11.14 vs 5.82; p<0.0001","unit":"HR; months; p","as_of":"2024-09-08","source":"https://www.smmttx.com/wp-content/uploads/2024/09/2024_PR_0908_WCLC-HARMONi-2-Data-_-FINAL-7.pdf","note":"China trial, primary analysis; not extrapolated to U.S. approval or efficacy in another indication."}],"sections":["01 | The gap: 0.057 versus 0.0448","02 | Why the FDA focused on survival","03 | Whose money is held up?","04 | The real test comes at year-end","05 | Three lessons for Taiwan's bispecific developers","References"],"references":[{"title":"Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application","source":"Summit Therapeutics","date":"2026-11-15","url":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx"},{"title":"Summit's global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend","source":"Fierce Biotech","date":"2025-09-07","url":"https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival"},{"title":"Summit Therapeutics Form 10-Q (as of 2026-06-30","source":"U.S. Securities and Exchange Commission","date":"2026-07-23","url":"https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm"},{"title":"FDA won't approve Summit, Akeso's ivonescimab","source":"pharmaphorum","date":"2026-11-15","url":"https://pharmaphorum.com/news/fda-wont-approve-summit-akesos-ivonescimab"},{"title":"Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy","source":"Eli Lilly","date":"2022-03-24","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-announces-complete-response-letter-sintilimab-combination"},{"title":"Merck Highlights Progress Advancing Broad, Diverse Pipeline","source":"Merck","date":"2026-02-03","url":"https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/"},{"title":"Merck Enters into Exclusive Global License for LM-299","source":"Merck","date":"2024-11-14","url":"https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/"},{"title":"Pfizer Enters into Exclusive Licensing Agreement with 3SBio","source":"Pfizer","date":"2025-05-19","url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio"},{"title":"AstraZeneca announces strategic equity investment in Summit; completes investment","source":"AstraZeneca","date":"","url":"https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment-summit.html"},{"title":"AP505 Greater China rights, excluding Taiwan, licensed to Tasly","source":"AP Biosciences","date":"2019-07-29","url":"https://www.apbioinc.com/news-detail12.htm"},{"title":"Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab","source":"Summit Therapeutics","date":"2024-09-08","url":"https://www.smmttx.com/wp-content/uploads/2024/09/2024_PR_0908_WCLC-HARMONi-2-Data-_-FINAL-7.pdf"},{"title":"Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026","source":"Summit Therapeutics","date":"2026-11-04","url":"https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/default.aspx"},{"title":"BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership for BNT327","source":"Bristol Myers Squibb","date":"2025-06-02","url":"https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple-Solid-Tumor-Types/default.aspx"}],"images":[{"alt":"Mechanisms of action of ivonescimab and Keytruda","url":"https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival-en/figure-01.png"},{"alt":"HARMONi primary-analysis results","url":"https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival-en/figure-02.png"},{"alt":"Upfront payments and maximum total values of four deals","url":"https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival-en/figure-03.png"},{"alt":"Ivonescimab licensing, approval and clinical-readout timeline","url":"https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-17）。FDA Rejects Akeso's Bispecific: PFS Was Not Enough。https://drugnews.com.tw/articles/2026-11-17-akeso-summit-ivonescimab-fda-crl-overall-survival-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “On November 15, 2026, Summit announced an FDA complete response letter for ivonescimab”?","a":"On November 15, 2026, Summit announced an FDA complete response letter for ivonescimab. HARMONi primary OS yielded p=0.057, missing the 0.0448 threshold."},{"q":"What are the key developments in “The original Akeso license was worth up to $5 billion”?","a":"The original Akeso license was worth up to $5 billion. Following the 2024 expansion, cumulative upfront payments reached $515 million, with up to $4.555 billion in milestones."},{"q":"What are the key developments in “HARMONi-3 squamous-cohort primary PFS and early interim OS analyses are expected in Q4 2026”?","a":"HARMONi-3 squamous-cohort primary PFS and early interim OS analyses are expected in Q4 2026; non-squamous PFS analysis is expected in H1 2027."}]}